Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Pleural Mesothelioma | Commentary

Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology

Authors: Tomer Meirson, Valerio Nardone, Francesca Pentimalli, Gal Markel, David Bomze, Maria D’Apolito, Pierpaolo Correale, Antonio Giordano, Luigi Pirtoli, Camillo Porta, Steven G Gray, Luciano Mutti

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

In this commentary, using existing clinical trial data and FDA approvals we propose that there is currently a critical need for an appropriate balancing between the financial impact of new cancer drugs and their actual benefit for patients. By adopting “pleural mesothelioma” as our clinical model we summarize the most relevant pertinent and available literature on this topic, and use an analysis of the reliability of the trials submitted for registration and/or recently published as a case in point to raise concerns with respect to appropriate trial design, biomarker based stratification and to highlight the ongoing need for balancing the benefit/cost ratio for both patients and healthcare providers.
Literature
1.
Correale P, Pentimalli F, Baglio G, Krstic-Demonacos M, Saladino RE, Giordano A, et al. Is there already a need of reckoning on cancer immunotherapy? Front Pharmacol. 2021;12:638279.CrossRef
2.
Chow RD, Bradley EH, Gross CP. Comparison of cancer-related spending and mortality rates in the US vs 21 high-income countries. JAMA Health Forum. 2022;3(5):e221229.CrossRef
3.
Zhang Y, Naci H, Wagner AK, Xu Z, Yang Y, Zhu J, et al. Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA Netw Open. 2022;5(8):e2225973.CrossRef
4.
5.
6.
Olivier T, Haslam A, Prasad V. Anticancer drugs approved by the US food and drug administration from 2009 to 2020 according to their mechanism of action. JAMA Netw Open. 2021;4(12):e2138793.CrossRef
7.
Vincent Rajkumar S. The high cost of prescription drugs: causes and solutions. Blood Cancer J. 2020;10(6):71.CrossRef
8.
Stacchiotti S, Schoffski P, Jones R, Agulnik M, Villalobos VM, Jahan TM, et al. Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950). J Clin Oncol. 2019;37(15_suppl):11003-.CrossRef
9.
Hoy SM. Tazemetostat. First Approval Drugs. 2020;80(5):513–21.
10.
11.
Rosenberg JE, O’Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592–600.CrossRef
12.
Li G, Liu X, Chen X. Simultaneous development of zanubrutinib in the USA and China. Nat Rev Clin Oncol. 2020;17(10):589–90.CrossRef
13.
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–82.CrossRef
14.
Marcus L, Donoghue M, Aungst S, Myers CE, Helms WS, Shen G, et al. FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors. Clin Cancer Res. 2021;27(4):928–32.CrossRef
15.
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):261–70.CrossRef
16.
Sartore-Bianchi A, Pizzutilo EG, Marrapese G, Tosi F, Cerea G, Siena S. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Expert Rev Anticancer Ther. 2020;20(5):333–41.CrossRef
17.
Shen C, Ferro EG, Xu H, Kramer DB, Patell R, Kazi DS. Underperformance of contemporary phase III oncology trials and strategies for improvement. J Natl Compr Canc Netw. 2021;19(9):1072–8.CrossRef
18.
Hahn AW, Dizman N, Msaouel P. Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive. Ther Adv Med Oncol. 2022;14:17588359221103200.CrossRef
19.
Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y, et al. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28(3):446–51.CrossRef
20.
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–86.CrossRef
21.
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488–99.CrossRef
22.
Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist. 2004;9(5):482–8.CrossRef
23.
Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, et al. A real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern. JTO Clin Res Rep. 2022;3(3):100280.
24.
25.
Tagliamento M, Bironzo P, Curcio H, De Luca E, Pignataro D, Rapetti SG, et al. A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. Crit Rev Oncol Hematol. 2022;172:103639.CrossRef
26.
27.
Bomze D, Asher N, Hasan Ali O, Flatz L, Azoulay D, Markel G, et al. Survival-inferred fragility index of phase 3 clinical trials evaluating immune checkpoint inhibitors. JAMA Netw Open. 2020;3(10):e2017675.CrossRef
28.
Bomze D, Azoulay D, Meirson T. Immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer. JAMA Oncol. 2020;6(7):1114–5.CrossRef
29.
Pak K, Uno H, Kim DH, Tian L, Kane RC, Takeuchi M, et al. Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio. JAMA Oncol. 2017;3(12):1692–6.CrossRef
30.
Gilboa S, Pras Y, Mataraso A, Bomze D, Markel G, Meirson T. Informative censoring of surrogate end-point data in phase 3 oncology trials. Eur J Cancer. 2021;153:190–202.CrossRef
31.
Meirson T, Pentimalli F, Cerza F, Baglio G, Gray SG, Correale P, et al. Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma. JAMA Netw Open. 2022;5(3):e221490.CrossRef
32.
Templeton AJ, Amir E, Tannock IF. Informative censoring—a neglected cause of bias in oncology trials. Nat Rev Clin Oncol. 2020;17(6):327–8.CrossRef
33.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–14.CrossRef
34.
Nord CL, Valton V, Wood J, Roiser JP. Power-up: a reanalysis of ‘power failure’ in neuroscience using mixture modeling. J Neurosci. 2017;37(34):8051–61.CrossRef
35.
Correale P, Pentimalli F, Nardone V, Giordano A, Mutti L. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? Lancet Oncol. 2022;23(1):e13.CrossRef
36.
Calabrò L, Rossi G, Morra A, Rosati C, Cutaia O, Daffinà MG, et al. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respir Med. 2021;9(9):969–76.CrossRef
37.
Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021;27(11):1910–20.CrossRef
38.
Fujimoto N, Okada M, Kijima T, Aoe K, Kato T, Nakagawa K, et al. Clinical efficacy and safety of nivolumab in Japanese patients with malignant pleural mesothelioma: 3-year results of the MERIT study. JTO Clin Res Rep. 2021;2(3):100135.
39.
Barbarino M, Bottaro M, Luzzi L, Giordano A, Mutti L. Tumour treating fields for mesothelioma. Lancet Oncol. 2020;21(1):e8.CrossRef
40.
Porta C, Nardone V, Gray SG, Correale P, Mutti L. RAMES study: is there really a role for VEGF inhibition in mesothelioma? Lancet Oncol. 2021;22(12):e532.CrossRef
41.
Nardone V, Porta C, Giannicola R, Correale P, Mutti L. Abemaciclib for malignant pleural mesothelioma. Lancet Oncol. 2022;23(6):e237.CrossRef
42.
Zabor EC, Kane MJ, Roychoudhury S, Nie L, Hobbs BP. Bayesian basket trial design with false-discovery rate control. Clin Trials. 2022;19(3):297–306.CrossRef
43.
Carbone M, Harbour JW, Brugarolas J, Bononi A, Pagano I, Dey A, et al. Biological mechanisms and clinical significance of BAP1 mutations in human cancer. Cancer Discov. 2020;10(8):1103–20.CrossRef
44.
LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015;21(11):1344–9.CrossRef
45.
Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, Taylor P, Planchard D, et al. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2022;23(6):758–67.CrossRef
46.
Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, et al. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro. BMC Cancer. 2019;19(1):108.CrossRef
47.
Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, et al. A Novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair. J Thorac Oncol. 2017;12(8):1309–19.CrossRef
48.
Ghafoor A, Mian I, Wagner C, Mallory Y, Agra MG, Morrow B, et al. Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in BAP1 gene. JTO Clin Res Rep. 2021;2(10):100231.
49.
Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir Med. 2021;9(6):593–600.CrossRef
50.
Dudnik E, Bar J, Moore A, Gottfried T, Moskovitz M, Dudnik J, et al. BAP1-altered malignant pleural mesothelioma: outcomes with chemotherapy, immune check-point inhibitors and poly(ADP-Ribose) polymerase inhibitors. Front Oncol. 2021;11:603223.CrossRef
51.
Pinton G, Manente AG, Murer B, De Marino E, Mutti L, Moro L. PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. J Cell Mol Med. 2013;17(2):233–41.CrossRef
52.
Gabano E, Pinton G, Balzano C, Boumya S, Osella D, Moro L, et al. Unsymmetric cisplatin-based Pt(IV) conjugates containing a PARP-1 inhibitor pharmacophore tested on malignant pleural mesothelioma cell lines. Molecules. 2021;26(16):4740.CrossRef
53.
Busacca S, Sheaff M, Arthur K, Gray SG, O’Byrne KJ, Richard DJ, et al. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol. 2012;227(2):200–8.CrossRef
54.
He Q, Zhang M, Zhang J, Zhong S, Liu Y, Shen J, et al. Predictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agents. Ann Transl Med. 2016;4(6):110.CrossRef
55.
Fennell DA, Porter C, Lester J, Danson S, Taylor P, Sheaff M, et al. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): a randomised, phase 2 trial. EClinicalMedicine. 2022;48:101432.CrossRef
56.
Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2012;70(5):743–54.CrossRef
57.
Busacca S, O’Regan L, Singh A, Sharkey AJ, Dawson AG, Dzialo J, et al. BRCA1/MAD2L1 deficiency disrupts the spindle assembly checkpoint to confer vinorelbine resistance in mesothelioma. Mol Cancer Ther. 2021;20(2):379–88.CrossRef
58.
Kumar N, Alrifai D, Kolluri KK, Sage EK, Ishii Y, Guppy N, et al. Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma. Lung Cancer. 2019;127:164–6.CrossRef
59.
Passiglia F, Bironzo P, Righi L, Listì A, Arizio F, Novello S, et al. A prospective phase II single-arm study of niraparib plus dostarlimab in patients with advanced non-small-cell lung cancer and/or malignant pleural mesothelioma, positive for PD-L1 expression and germline or somatic mutations in the DNA repair genes: rationale and study design. Clin Lung Cancer. 2021;22(1):e63–6.CrossRef
60.
Cedres S, Assaf JD, Iranzo P, Callejo A, Pardo N, Navarro A, et al. Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort. Sci Rep. 2021;11(1):21357.CrossRef
61.
Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933–80.CrossRef
62.
Pirtoli L, Alia L, Zacchini S. Oncology and a time of crisis. Science, complexity, ethic values, and incertitude. An argumentative essay. Medicus. 2021;5:104–17.
63.
Yang L, Cao X, Li N, Zheng B, Liu M, Cai H. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma. Ther Adv Med Oncol. 2022;14:17588359221116604.CrossRef
64.
Ye ZM, Tang ZQ, Xu Z, Zhou Q, Li H. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma. Front Public Health. 2022;10:947375.CrossRef
65.
Michaeli DT, Michaeli T. Overall Survival, Progression-free survival, and tumor response benefit supporting initial US food and drug administration approval and indication extension of new cancer drugs, 2003-2021. J Clin Oncol. 2022;JCO2200535. https://​doi.​org/​10.​1200/​JCO.​22.​00535 (Epub ahead of print. PMID: 35921606)
66.
Fennell DA, Kirkpatrick E, Cozens K, Nye M, Lester J, Hanna G, et al. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials. 2018;19(1):233.CrossRef
67.
Borrelli EP, McGladrigan CG. A review of pharmacologic management in the treatment of mesothelioma. Curr Treat Options Oncol. 2021;22(2):14.CrossRef
68.
Cordony A, Le Reun C, Smala A, Symanowski JT, Watkins J. Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice. Value Health. 2008;11(1):4–12.CrossRef
69.
Zhan M, Zheng H, Xu T, Yang Y, Li Q. Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial. Lung Cancer. 2017;110:1–6.CrossRef
70.
Louw A, Panou V, Szejniuk WM, Meristoudis C, Chai SM, van Vliet C, et al. BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study. J Thorac Oncol. 2022;17(7):921–30.CrossRef
71.
Guazzelli A, Meysami P, Bakker E, Demonacos C, Giordano A, Krstic-Demonacos M, et al. BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment. Int J Mol Sci. 2019;20(2):429.CrossRef
72.
Oehl K, Vrugt B, Wagner U, Kirschner MB, Meerang M, Weder W, et al. Alterations in BAP1 are associated with cisplatin resistance through inhibition of apoptosis in malignant pleural mesothelioma. Clin Cancer Res. 2021;27(8):2277–91.CrossRef
73.
Fennell DA, King A, Mohammed S, Greystoke A, Anthony S, Poile C, et al. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2022;23(3):374–81.CrossRef
74.
Strzebonska K, Waligora M. Umbrella and basket trials in oncology: ethical challenges. BMC Med Ethics. 2019;20(1):58.CrossRef
75.
Janiaud P, Serghiou S, Ioannidis JPA. New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treat Rev. 2019;73:20–30.CrossRef
76.
Kindler HL. Systemic therapy for mesothelioma: turning the corner. JCO Oncol Pract. 2022;18(6):e843–5.
77.
Nowak AK, Jackson A, Sidhu C. Management of advanced pleural mesothelioma-at the crossroads. JCO Oncol Pract. 2022;18(2):116–24.CrossRef
78.
Fennell DA, Dulloo S, Harber J. Immunotherapy approaches for malignant pleural mesothelioma. Nat Rev Clin Oncol. 2022;19(9):573–84.CrossRef
79.
Ratain MJ. Oncology drug prescribing: the influences of greed and fear. JCO Oncol Pract. 2022;18(9):e1384–7.
Metadata
Title
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
Authors
Tomer Meirson
Valerio Nardone
Francesca Pentimalli
Gal Markel
David Bomze
Maria D’Apolito
Pierpaolo Correale
Antonio Giordano
Luigi Pirtoli
Camillo Porta
Steven G Gray
Luciano Mutti
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03744-6

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Research

Circular RNA circLOC101928570 suppresses systemic lupus erythematosus progression by targeting the miR-150-5p/c-myb axis

Letter to the Editor

Poor oral health may prolong COVID-19 illness

Research

Body mass index, genetic susceptibility, and Alzheimer's disease: a longitudinal study based on 475,813 participants from the UK Biobank

Research

Transcriptome-based network analysis related to M2-like tumor-associated macrophage infiltration identified VARS1 as a potential target for improving melanoma immunotherapy efficacy

Research

Noninvasive prediction of axillary lymph node status in breast cancer using promoter profiling of circulating cell-free DNA

Research

Identification of immune-related key genes in the peripheral blood of ischaemic stroke patients using a weighted gene coexpression network analysis and machine learning
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits